Background:  The purpose of PARAGON is to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular (CV) death and HF hospitalizations in patients with HF with preserved EF (HFpEF) Trial Registration No: NCT02625922 ( Link  Trial Status: Randomized worldwide: 4600, Recruitment stopped Randomized in Basel: 7 Enrolling Centers:  Switzerland Worldwide: Basel, Zürich, Bern, Lausanne,   39 in different countries  Biel, Lugano Core Study Team: 
© Christian Mueller, 2012 - 2019 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: May 2019
Jasmin Martin Home News Team Studies Publications Events Cooperations Contact Kristin Podkowik Bettina Glatz Beate Hartmann Ph.D. Derya Kilinc Eleni Michou